Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) Equity Average (2021 - 2025)

Senti Biosciences has reported Equity Average over the past 5 years, most recently at $6.9 million for Q4 2025.

  • Quarterly results put Equity Average at $6.9 million for Q4 2025, down 67.08% from a year ago — trailing twelve months through Dec 2025 was $6.9 million (down 67.08% YoY), and the annual figure for FY2025 was $15.6 million, down 66.25%.
  • Equity Average for Q4 2025 was $6.9 million at Senti Biosciences, down from $16.4 million in the prior quarter.
  • Over the last five years, Equity Average for SNTI hit a ceiling of $147.3 million in Q3 2022 and a floor of -$116.6 million in Q1 2022.
  • Median Equity Average over the past 5 years was $31.3 million (2025), compared with a mean of $28.0 million.
  • Biggest five-year swings in Equity Average: soared 546.22% in 2023 and later crashed 72.21% in 2024.
  • Senti Biosciences' Equity Average stood at -$106.4 million in 2021, then surged by 225.74% to $133.8 million in 2022, then plummeted by 44.0% to $74.9 million in 2023, then crashed by 72.21% to $20.8 million in 2024, then plummeted by 67.08% to $6.9 million in 2025.
  • The last three reported values for Equity Average were $6.9 million (Q4 2025), $16.4 million (Q3 2025), and $31.3 million (Q2 2025) per Business Quant data.